

Table SI. Treatment timeline and outcome measures across all patients

Patient		Prior therapies			Anifrolumab treatment			Clinical response				Safety
Pt.	Age/Sex/ Diagnosis	Prior therapy	Duration (months)	Reason for discontinuation	Start (MM/YYYY)	Treatment duration (months)	Concomitant medication	Time to clinical response (months)	CLASI baseline	CLASI at follow-up	Long-term maintenance	Adverse events
1	47 F/DLE Aab negative (midface)	HCQ MTX MTX AZA MMF	1 5 12 17 Once	Exanthema Inefficacy Inefficacy Inefficacy Inefficacy	08/2024	≥12 months	None	2	CLASI-A 10 CLASI-D 4	CLASI-A 1, CLASI-D 2	Sustained	None
2	64 F/DLE Aab negative (face & scalp, scarring)	CQ, intermittent HCQ MTX MMF CS pulse	260 80 6 3 5 1	Effective, withdrawn from market Inefficacy Inefficacy Inefficacy, GI side-effects Inefficacy, GI side-effects Inefficacy	04/2024	≥12 months	None	3	CLASI-A 19 CLASI-D 3	CLASI-A 5 CLASI-D 3	Partial; progressive alopecia noted	Progressive alopecia (uncertain attribution)
3	57 M/DLE Aab negative (face, neck, ears)	HCQ HCQ+AZA HCQ+MTX MMF / MPA Tofacitinib CS pulse	84 56 8 8 7 1	Inefficacy, fatigue, impaired concentration Inefficacy Headache, dizziness Inefficacy Inefficacy Inefficacy	09/2024	≥12 months	None	2	CLASI-A 11 CLASI-D 2	CLASI-A 0 CLASI-D 1	Sustained; pruritus resolved	None
4	61 F/DLE anti-dsDNA+, anti-SSA+; (no full SLE criteria) CLE disseminated, alopecia	HCQ MTX	20 17	Limited efficacy, severe hyperpigmentation Continued	05/2024	≥12 months	MTX+HCQ reintroduced (systemic progression concern)	3	CLASI-A 4 CLASI-D 5	CLASI-A 0 CLASI-D 5	Reduction of inflammatory activity; residual hypopigmentation	None
5	58 F/DLE Aab negative (face, décolleté, back, scalp, lips)	HCQ CS pulse therapy MTX AZA MMF Upadacitinib	4 1 8 7 8 12	Inefficacy (lip lesions), s/o drug-induced toxic myopathy Inefficacy (lip lesions), GI side-effects Inefficacy (lip lesions), GI side-effects Inefficacy (lip lesions), leukopenia Inefficacy (lip lesions), GI side-effects Inefficacy (lip lesions), CK elevation and myalgia	10/2025	≥6 months	None	6	CLASI-A 3 CLASI-D 8	CLASI-A 0 CLASI-D 8	Labial inflammation resolved; permanent scarring (CLASI- D stable)	Chills, arthralgia (infusions 1– 2, self- limiting); cystitis (×1, resolved with antibiotics)